Accessing Pharma Markets In Eastern Europe With Fleming Europe, 4-5 October 2012, Budapest

Date: Sep-18-2012Tightening regulations, increasing healthcare costs, ever-growing budget restrictions - these are just a few of the concerns that are raising the attention of key pharma stakeholders throughout the region of CEE, CIS, SEE countries and Turkey. In this new market reality, pharma companies still need to find a way to capture maximum business potential in these key regions.

In order to discuss major concerns and overcome challenges resulting from these tendencies throughout the region, Fleming Europe is organizing a brand new conference - Pharma Excellence in the CEE, CIS, SEE and Turkey. A number of top-level pharmaceutical experts have accepted the invitation to present their strategies to accelerate market access and to ensure maximum return on investment, in the beautiful city of Budapest, on 4 - 5 October 2012.

"Fleming Europe has decided to create a platform where leading Pharma specialists from Turkey and countries of the CEE, CIS and SEE would gather to discuss and to resolve the most pressing issues dominating the region," Jana Chocholova, conference producer explained.

This 2-day conference will be structured into presentations and interactive panel discussions focused on topics such as - opportunities and challenges within diversified market environments, the importance of clinical and economic value in market access, major regulatory concerns, payers' roles in the entire product life-cycle, critical insight into the HTA processes in the region, successful pathways for product launch, closed loop marketing, strategies to increase SFE and many more.

Regional pharmaceutical experts from Eli Lilly, Novartis, Teva, Zentiva, Mylan, Pfizer, Sanofi, Merck, Roche, GSK, AstraZeneca, Abbott, etc. will participate in this unique conference to share their knowledge and experience with you.

PHARMA COMMERCIAL EXCELLENCE in CEE, CIS, SEE & Turkey
Courtesy: Medical News Today Note: Any medical information available in this news section is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.